- Conditions
- Acne
- Interventions
- Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel, Vehicle Gel
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 27
- States / cities
- San Diego, California • Denver, Colorado • Longmont, Colorado + 24 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 17,796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ulcerative Colitis
- Interventions
- Given® Diagnostic System
- Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
- Interventions
- Epanova® (omega-3 carboxylic acids), corn oil control
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 13,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 229
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 183 more
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- PTC596, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Ischemic Stroke
- Interventions
- intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
- Drug · Device
- Lead sponsor
- Penumbra Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Gainesville, Florida • Chicago, Illinois + 1 more
- Conditions
- Premature Birth, Asthma in Children, Sleep-Disordered Breathing, Neurodevelopmental Disorders
- Interventions
- Not listed
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 30 Weeks to 83 Months
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
- Interventions
- Ubamatamab, Marlotamig, Sarilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 14 more
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
- Interventions
- Apitegromab, Placebo
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 23 more
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
- Interventions
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 581
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more
- Conditions
- Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma
- Interventions
- conventional surgery, dactinomycin, cyclophosphamide, vincristine sulfate, radiation therapy
- Procedure · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 49 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2021
- U.S. locations
- 138
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 113 more
- Conditions
- HIV-1 Infection
- Interventions
- elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • San Diego, California • Torrance, California + 17 more
- Conditions
- Lower Urinary Tract Symptoms
- Interventions
- None- Observational Study
- Other
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 3 more
- Conditions
- Primary Generalized (Osteo)Arthritis, Post-traumatic Arthrosis of Other Joints, Upper Arm
- Interventions
- Simpliciti™ Shoulder System
- Device
- Lead sponsor
- Stryker Trauma and Extremities
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 14
- States / cities
- Fresno, California • La Mesa, California • New Haven, Connecticut + 11 more
- Conditions
- Tardive Dyskinesia
- Interventions
- NBI-98854, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 48
- States / cities
- Little Rock, Arkansas • Anaheim, California • Glendale, California + 45 more
- Conditions
- Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
- Interventions
- CTX001
- Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Chicago, Illinois • New York, New York + 2 more
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Interventions
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR), Placebo
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 33 more
- Conditions
- Venous Thromboembolism
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- Glaucoma Surgery, InnFocus MicroShunt
- Procedure · Device
- Lead sponsor
- InnFocus Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 732 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 24
- States / cities
- Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
- Conditions
- PreDiabetes
- Interventions
- Decision Aid intervention, Text Messaging intervention, Usual Care
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 960 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Shoulder Fractures, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Deformity, Shoulder Injuries, Shoulder Pain
- Interventions
- Alliance Glenoid, Identity Stem
- Device
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2033
- U.S. locations
- 12
- States / cities
- Irvine, California • Golden, Colorado • Chicago, Illinois + 9 more
- Conditions
- Stroke
- Interventions
- Isometric contractions, Isokinetic contractions, Dynamic contractions, Isometric contraction with muscle fatigue, Multi-joint functional activities while wearing exoskeleton, Clinical Assessments
- Other · Device
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- HIV Infections
- Interventions
- VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C), rAd5 env A, rAd5 env B, rAd5 env C, rAd5 gag-pol, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 8
- States / cities
- San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ABT-348, ABT-348 and carboplatin, ABT-348 and docetaxel
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Houston, Texas
- Conditions
- Advanced Solid Malignancies
- Interventions
- AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 695 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 11
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 7 more